Thromboembolic diseases impose a significant burden on global health. However, the currently approved anticoagulant drugs, including heparin, vitamin K antagonists, and direct oral anticoagulants (DOACs), all carry certain bleeding risks. The proteases inhibited by these drugs play crucial roles in both pathological th...
Hui Yuan, Yuan-Yuan He, Mao Zhang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.